National Bank of Canada FI Has $53,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

National Bank of Canada FI boosted its stake in Royalty Pharma plc (NASDAQ:RPRX) by 21.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,074 shares of the biopharmaceutical company’s stock after acquiring an additional 371 shares during the quarter. National Bank of Canada FI’s holdings in Royalty Pharma were worth $53,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Swedbank AB lifted its holdings in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after purchasing an additional 1,136,800 shares in the last quarter. Geode Capital Management LLC lifted its stake in Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after acquiring an additional 417,490 shares in the last quarter. Norges Bank acquired a new position in Royalty Pharma during the 4th quarter worth approximately $124,498,000. Charles Schwab Investment Management Inc. grew its stake in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock worth $79,888,000 after acquiring an additional 130,025 shares in the last quarter. Finally, New South Capital Management Inc. grew its stake in shares of Royalty Pharma by 19.9% during the 4th quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company’s stock worth $75,436,000 after acquiring an additional 490,754 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $31.95 on Friday. The company has a fifty day moving average price of $32.50 and a two-hundred day moving average price of $29.14. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The stock has a market cap of $18.42 billion, a P/E ratio of 22.03, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several recent research reports. Citigroup restated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.